| Literature DB >> 28119606 |
Minghua Liu1, Ge Zhao1, Shousong Cao1, Yangyang Zhang1, Xiaofang Li1, Xiukun Lin1.
Abstract
Traditional Chinese medicines (TCMs) have been used in China for more than two thousand years, and some of them have been confirmed to be effective in cancer treatment. Protein kinases play critical roles in control of cell growth, proliferation, migration, survival, and angiogenesis and mediate their biological effects through their catalytic activity. In recent years, numerous protein kinase inhibitors have been developed and are being used clinically. Anticancer TCMs represent a large class of bioactive substances, and some of them display anticancer activity via inhibiting protein kinases to affect the phosphoinositide 3-kinase, serine/threonine-specific protein kinases, pechanistic target of rapamycin (PI3K/AKT/mTOR), P38, mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases (ERK) pathways. In the present article, we comprehensively reviewed several components isolated from anticancer TCMs that exhibited significantly inhibitory activity toward a range of protein kinases. These components, which belong to diverse structural classes, are reviewed herein, based upon the kinases that they inhibit. The prospects and problems in development of the anticancer TCMs are also discussed.Entities:
Keywords: ERK; MAPK; PI3K/AKT/mTOR; Traditional Chinese Medicine; anticancer activity; protein kinase inhibitors
Year: 2017 PMID: 28119606 PMCID: PMC5220067 DOI: 10.3389/fphar.2016.00523
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Schematic depiction of TCM components that serve as protein kinase inhibitors. The PI3K/AKT/mTOR, P38 MAPK, and ERK pathways are important players in cell death induced by protein kinases. Many compounds isolated from TCMs are capable of inducing cell death via affecting different protein kinase pathways.
Figure 2Chemical structures of components isolated from TCMs with inhibitory effects via MAPK pathway.
Figure 3Chemical structures of components isolated from TCMs with inhibitory effects on PI3K/AKT pathway.
Figure 4Chemical structures of components isolated from TCM that target Epidermal Growth Factor Receptor (EGFR).
A summary of Traditional Chinese Medicines as kinase inhibitors.
| Curcuma | Polyphenols | JNK/p38 MAPK/ERK HCT-116, THP-1, CNE1, CNE2, and HepG2 cells | Collett and Campbell, | |
| Celastrol | Triterpene | JNK HOS, MG-63, U-2OS, and Saos-2 cells | Li H. Y. et al., | |
| Chelerythrine | Benzophen anthridine alkaloid | JNK/p38 MAPK/ERK Hela, HOS, and U-2OS cells | Yu et al., | |
| Emodin | Anthraquinone | ERK/p38 MAPK SMMC-7721, SW480, and SW620 cells | Liu et al., | |
| Tubeimoside-1 | Triterpenoid saponin | JNK/p38 MAPK/ERK DU145, A549, PC9 A2780/DDP, SKOV-3. and HepG2 cells | Liu H. Z. et al., | |
| β-eudesmol | Sesquiterpenol | JNK HL60 cell | Li Y. et al., | |
| Hinesol | Sesquiterpenol | JNK/ERK HL60 cell | Masuda et al., | |
| Isoquercitrin | Favonoid | JNK/p38 MAPK/ERK HepG2 cell | Huang et al., | |
| PYDDT | Alkynol group- substituted thiophene | JNK SW620 cell | Xu et al., | |
| Tatariside G | Phenylpropan- oid glycosides | JNK/p38 MAPK HeLa cell | Li et al., | |
| SYUNZ-16 | b,b-dimethylacrylalkannin | AKT Hep3B and GLC-82 cells | Deng et al., | |
| Arenobufagin | C24 steroids | PI3K/Akt/mTOR HepG2 and HepG2/ ADM cells | Zhang D. M. et al., | |
| Tetrandrine | Bisbenzylisoquinoline alkaloid | ERK and PI3K/AKT HT-29, Huh7, HepG2 and BEL7402 cells | Chen et al., | |
| β-Elemene | Terpene | PI3K/Akt/mTOR MGC803 and SGC7- 901cells | Liu C. Y. et al., | |
| Pogostone | Ketone | PI3K/Akt/mTOR HCT116 cell | Cao et al., | |
| Chamaejasmine | Flavonoid | PI3K/Akt HeLa and HEp-2 cells. | Wang et al., | |
| Resveratrol | Polyphenol | PI3K/Akt MGC803 cell | Jing et al., | |
| Ophiopogonin-B | Saponin | PI3K/Akt/mTOR NCI-H157, H460 and HeLa cells | Chen M. et al., | |
| Ginsenoside Rg3 | Saponin | EGFR and VEGF A549, H1299, H358, MCF-7 and HUVEC304 cells | Chen et al., | |
| Icariside II | Flavonoid | EGFR A431 cell | Wu et al., | |
| Platycodin D | Saponin | EGFR MDA-MB-231 cell | Chun and Kim, | |
| Myrislignan | Lignans | EGFR A549 cell | Lu et al., | |
| OA | Triterpene | EGFR A549 cell | Wang et al., | |
| VS1 | Heterocycle | ERBB3 A549 cell | Guo et al., |